Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us
Our Innovative Portfolio & Pipeline

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces Corporate Update

View Press Release

Baudax Bio Announces Corporate Update

View Press Release

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

View Press Release

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

View Press Release

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

View Press Release

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

View Press Release

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

View Press Release

Baudax Bio Acquires TeraImmune, Inc.

View Press Release

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

View Press Release

Baudax Bio Announces Date of Reconvened Annual Meeting

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today